Shots:
- The companies collaborated for CDx development of tepotinib in mainland China. The CDx test is based on Burning Rock’s OncoCompass target which is a self-developed NGS-based liquid biopsy solution
- Burning Rock will be responsible for the research and development of tumor genetic testing for cancer patients with the precision medicine solutions
- Tepotinib is an oral MET inhibitor that inhibits the oncogenic MET receptor signaling caused by MET (gene) alterations. The therapy is available in other countries and is under review by multiple regulatory authorities globally
Click here to read full press release/ article | Ref: Globenewswire | Image: Merck
The post Merck KGaA Collaborated with Burning Rock for Liquid-biopsy Based CDx Development first appeared on PharmaShots.
